Ascendis Pharma A/S expected to post a loss of €2.59 a share - Earnings Preview

Ascendis Pharma A/S

11/08/2023 12:30

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 14
(estimated). 
    * The Hellerup Denmark-based   company is expected to report
 a
506.3% increase in revenue to €37.35 million from €6.16 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ascendis Pharma A/S
is
for a loss of €2.59 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $146​, above​ its last closing price of $90.53. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -2.65       -2.66      -1.98     Beat    25.6
 Dec. 31 2023  -2.44       -2.56      -3.70     Missed  -44.5
 Sep. 30 2022  -2.49       -2.49      -3.03     Missed  -21.7​
 Jun. 30 2022  -2.08       -2.13      -1.46     Beat    31.5
 ​​Mar.        -1.98       -2.00      -2.21     Missed  -10.5
 31 2022                                                
 Dec. 31 2021  -2.39       -2.34      -1.87     Beat    20.2​
 Sep. 30 2021  -2.30       -2.29      -1.47     Beat    35.9
 Jun. 30 2021  -2.22       -2.23      -2.50     Missed  -12.3
 This summary was machine generated August 11 at 11:30 GMT.  All
figures in euros  unless otherwise stated